You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物(02197.HK)回應新冠疫苗生產:適時調整業務資源投入
阿思達克 01-11 14:04
內地傳媒近日報道,科興已停產新冠疫苗,《澎湃新聞》引述三葉草生物(02197.HK)回應指,目前新冠疫苗在國內外需求量相對較低,但新冠病毒仍然客觀存在,而且不斷變異,公司一直關注新冠疫苗的業務機會,亦會適時根據市場的變化,調整關於新冠業務的資源投入。 三葉草生物的新冠疫苗SCB-2019(CpG 1018鋁佐劑)於2022年底在國內被納入緊急使用,其新冠疫苗曾在北京、成都等地開打。三葉草生物指,若果新冠疫苗有機會在中國進入自費市場,可能會有更大的商業化價值及更可持續的市場機會。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account